# Lipoprotein(a) [Lp(a)] & ApoB Dual Atherogenic Particle Decoder & Chrono-Dosing Protocol

- **Platform**: NuraDose (`https://nuradose.com`)
- **Application Scenario**: Longevity Cardiology & Genetic Lp(a) Risk Management (+490% YoY Search Growth)
- **Canonical URL**: `https://nuradose.com/biomarkers/lp-a-lipoprotein-little-a-apob-niacin-pcsk9-natural-lowering-protocol.html`

## Executive Summary
Why 20% of Fit Adults Have Genetically High Lp(a) (>50 mg/dL or >125 nmol/L) and How to Crush Residual Vascular Risk

## 2026 Quantitative Benchmark Matrix
| Key Parameter / Component | Conventional Baseline / Risk | 2026 Optimal Target / Benchmark | Actionable Execution Protocol |
| :--- | :--- | :--- | :--- |
| Lipoprotein(a) [Lp(a)] | < 30 mg/dL (< 75 nmol/L) | 14–30 mg/dL (< 35 nmol/L) | L-Carnitine (2,000mg AM) + Tocotrienols + CoQ10 |
| Apolipoprotein B (ApoB) | < 100 mg/dL | < 60 mg/dL (If Lp(a) is elevated) | Citrus Bergamot (1,000mg) + Soluble Fiber + rTG EPA |
| Oxidized Phospholipids (OxPL-apoB) | Unmeasured on standard panels | hs-CRP < 0.6 mg/L + Homocysteine < 7.0 | Aged Garlic Extract (1,200mg) + Vitamin K2 MK-7 |

## Application Scenario & Execution Blueprint
Clinical Application Scenario: Since Lp(a) is 80% genetically determined, clinical longevity medicine targets crushing ApoB below 60 mg/dL and neutralizing endothelial inflammation so Lp(a) particles cannot plaque arterial walls.